Skip to main content
main-content
Top

11-05-2017 | Biosimilars | Article

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Please follow the link below to view this article in full on a third party website. Note that a subscription or payment may be required.

Please log in to get access to this content

Related topics